Pharma BD Deal Intelligence
GSK's oncology bet on Arzerra flopped commercially; it then sold off the asset that became Novartis's multi-billion-dollar MS blockbuster Kesimpta, capturing only a capped royalty/milestone stream of the eventual upside.
Full analysis, sources & comparables →Genmab shares surged as much as 24% to an all-time high; Jyske Bank analyst Frank Andersen raised his rating to 'buy', forecasting peak ofatumumab sales of…
PharmaTimes framed the GSK alliance as potentially worth over GBP 1 billion to Genmab, a transformative validation of the small Danish biotech's…
Novartis acquired ofatumumab rights from the GSK-Genmab collaboration in 2014, and Arzerra was withdrawn from non-US markets by 2019 as commercial uptake…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Anti-CD20 mAb (Arzerra); $102M upfront + $357M equity + up to $1.6B milestones; record biotech license deal at the time
GSK's oncology bet on Arzerra flopped commercially; it then sold off the asset that became Novartis's multi-billion-dollar MS blockbuster Kesimpta, capturing only a capped royalty/milestone stream of the eventual upside.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Genmab A/S (ofatumumab/HuMax-CD20) (this deal) | 2006 | $2.1B | 35 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2006 deals · GlaxoSmithKline plc deals